Pascal Soriot

AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. The deal would combine AstraZeneca's nearly £196bn market value with BMS's $133bn valuation.

AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. AstraZeneca, the UK’s second-biggest listed company, has a market value of nearly £196bn, while BMS, based in Princeton, is valued at $133bn.

Chinese pharmaceutical companies are advancing in early-stage research and clinical trials but remain about a decade behind global leaders like AstraZeneca. AstraZeneca's CFO, Aradhana Sarin, noted that Chinese firms lack the capability for global clinical trials but may challenge Western competitors within 10 years. The rise of GLP-1 drugs for weight loss could reshape pharmaceutical strategies and cancer prevalence patterns.

AstraZeneca CEO Pascal Soriot warns that the US and European pharmaceutical industries risk falling behind China's rising pharmaceutical sector due to slower innovation. He urges Western drugmakers to adopt a faster pace, citing the automotive industry as an example of past stagnation.

AstraZeneca chief Pascal Soriot warns that the company may withhold new drugs in Europe unless countries increase spending on innovative medicines following a US trade deal.

AstraZeneca CEO Pascal Soriot stated that AI is accelerating drug development and improving decision-making in research. He highlighted AI's role in increasing the likelihood of success for medicine development.

AstraZeneca CEO Pascal Soriot delivered remarks as the company celebrated its transfer to the NYSE. The event marks a significant milestone for the firm's stock market presence.